Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 6/20 | 0.47 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367683 | 1.00 | PNP (0.47) | PNPTK1ADRB1DNMT1POLA1 | |
| SCHEMBL22399465 | 0.88 | PNP (0.44) | PNPTK1POLA1POLB | |
| SCHEMBL29875802 | 0.84 | POLB (0.46) | PNPPOLA1POLB | |
| SCHEMBL8185378 | 0.81 | POLB (0.59) | PNPPOLA1POLB | |
| SCHEMBL6421906 | 0.81 | POLB (0.59) | PNPPOLA1POLB | |
| SCHEMBL26787693 | 0.81 | TK1 (0.46) | PNPTK1ADRB1DNMT1POLA1 | |
| SCHEMBL655858 | 0.81 | PNP (0.65) | PNPTK1ADRB1DNMT1POLB | |
| SCHEMBL21637039 | 0.81 | TK1 (0.46) | PNPTK1ADRB1DNMT1POLA1 | |
| SCHEMBL655857 | 0.81 | PNP (0.65) | PNPTK1ADRB1DNMT1POLB | |
| SCHEMBL21779018 | 0.80 | PNP (0.55) | PNPTK1ADRB1DNMT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150389-A1 | MODIFIED GUANINES | NUCLERA LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2022175685-A1 | MODIFIED GUANINES | NUCLERA NUCLEICS LTD (GB) | 2022-08-25 | — | — | WO | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| EP-3823976-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | Janssen Biotech, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112424212-A | Cyclic dinucleotides as STING agonists | 詹森生物科技公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020016782-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-1999050441-A1 | A SELECTIVE ASSAY FOR DETERMINING THE IDENTITY OF LIVE MICROORGANISMS IN A MIXED CULTURE | SAIGENE CORPORATION (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5789562-A | STABLE HYBRIDIZATION COMPLEXES WITH NUCLEI ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-04 | — | — | US | disclosed |
| EP-0305201-B1 | Protected biotin derivatives | ZENECA LTD (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0680969-A2 | Modified oligonucleotides, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-08 | — | — | EP | disclosed |
| EP-0238329-B1 | Improvements in genetic probes | ZENECA LTD (GB) | 1994-04-27 | — | — | EP | disclosed |
| US-5247081-A | Labeled polynucleotide probes used as diagnostic tools for clinical and research uses | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-09-21 | — | — | US | disclosed |
| US-5175082-A | Fragmenting sample with restriction enzyme, probing DNA fragments with a polynucleotide which hybridize to a single miinisatellite region, detecting hybridized fragment of DNA, comparing it with control; use for genetic identification | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-12-29 | — | — | US | disclosed |
| EP-0305201-A2 | Protected biotin derivatives | ZENECA LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |
| EP-0238329-A2 | Improvements in genetic probes | ZENECA LIMITED (GB) | 1987-09-23 | — | — | EP | disclosed |
| US-4543255-A | Carbocyclic analogs of purine 2'-deoxyribofuranosides | SOUTHERN RESEARCH INSTITUTE (US) | 1985-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PNP 313/4885TK1 430/4885ADRB1 163/4885 |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PNP 319/4885TK1 414/4885ADRB1 186/4885 |
| US-20240150389-A1 | MODIFIED GUANINES | NSUN2, RNMT, RNGTT | PNP 72/4885TK1 374/4885ADRB1 3549/4885 |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, IFNAR1 | PNP 319/4885TK1 414/4885ADRB1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.